A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 5, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the XRAY SEC filings page.
DENTSPLY SIRONA Inc. (XRAY) reported $3.6B in revenue over the twelve months to Sep 30, 2026, down 1.4% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Cost reductions have narrowed losses, while weaker cash generation and rising leverage show the business remains financially pressured.
Revenue fell from$3.97B in FY2023 to$3.68B in FY2025, indicating the business has not regained volume. Operating cash flow fell from$377M to$235M over the same span even as operating losses narrowed in FY2025; the accounting recovery therefore did not restore cash conversion.
Gross margin fell from
Liabilities reached
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of DENTSPLY SIRONA Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. DENTSPLY SIRONA Inc. scores 18/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. DENTSPLY SIRONA Inc. scores 19/100 on it among other operating companies.
DENTSPLY SIRONA Inc. carried $1.50 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2025, a debt-to-equity ratio of 1.50. With no positive EBITDA in fiscal year 2025, DENTSPLY SIRONA Inc. is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 22/100 among other operating companies measured the same way.
DENTSPLY SIRONA Inc. held $1.51 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.51. Liquidity ranks operating companies on that ratio, and DENTSPLY SIRONA Inc. scores 43/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. DENTSPLY SIRONA Inc. scores 45/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. DENTSPLY SIRONA Inc. scores 19/100 on it among other operating companies.
DENTSPLY SIRONA Inc. scores 0.41, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $1.6B against total assets of $5.4B. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
DENTSPLY SIRONA Inc. passes 5 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
DENTSPLY SIRONA Inc. reported a net loss of $598.0M while generating $235.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
DENTSPLY SIRONA Inc. reported an operating loss of $422.0M against $88.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
DENTSPLY SIRONA Inc. generated $836.0M in revenue in Q3 2026. This represents a decrease of 7.5% from the same quarter a year earlier. Against the prior quarter it is down 6.9%.
DENTSPLY SIRONA Inc.'s EBITDA was $119.0M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 28.7%.
DENTSPLY SIRONA Inc. reported a net loss of $2.0M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 105.4%.
DENTSPLY SIRONA Inc. earned -$0.01 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is down 105.6%.
Cash & Balance Sheet
DENTSPLY SIRONA Inc. generated $0 in free cash flow in Q3 2026, representing cash available after capex. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
DENTSPLY SIRONA Inc. held $195.0M in cash against $2.0B in long-term debt as of Q3 2026.
Not reported for Q3 2026.
Margins & Returns
DENTSPLY SIRONA Inc.'s gross margin was 53.0% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 4.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.9 percentage points.
DENTSPLY SIRONA Inc.'s operating margin was 4.4% in Q3 2026, reflecting core business profitability. This is up 28.5 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.7 percentage points.
DENTSPLY SIRONA Inc.'s net profit margin was -0.2% in Q3 2026, showing the share of revenue converted to profit. This is up 47.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 4.4 percentage points.
DENTSPLY SIRONA Inc.'s quarterly ROE was -0.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 28.7 percentage points from the same quarter a year earlier. Against the prior quarter it is down 2.9 percentage points.
Capital Allocation
DENTSPLY SIRONA Inc. invested $42.0M in research and development in Q3 2026. This represents an increase of 13.5% from the same quarter a year earlier. Against the prior quarter it is down 6.7%.
DENTSPLY SIRONA Inc. spent $13.0M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
DENTSPLY SIRONA Inc. invested $32.0M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 17.9% from the same quarter a year earlier. Against the prior quarter it is down 27.3%.
XRAY Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $836.0M-7.5% | $898.0M-4.1% | $880.0M+0.1% | $961.0M+6.2% | $904.0M-4.9% | $936.0M-4.9% | $879.0M-7.8% | $905.0M-10.6% |
| Cost of Revenue | $393.0M-15.1% | $405.0M-9.2% | $453.0M+9.7% | $518.0M+12.9% | $463.0M+1.5% | $446.0M-5.7% | $413.0M-7.6% | $459.0M-6.3% |
| Gross Profit | $443.0M+0.5% | $493.0M+0.6% | $427.0M-8.4% | $443.0M-0.7% | $441.0M-10.9% | $490.0M-4.1% | $466.0M-7.9% | $446.0M-14.6% |
| R&D Expenses | $42.0M+13.5% | $45.0M+21.6% | $44.0M+22.2% | $40.0M-4.8% | $37.0M-7.5% | $37.0M-9.8% | $36.0M-14.3% | $42.0M-2.3% |
| SG&A Expenses | $363.0M+2.3% | $364.0M+6.4% | $351.0M-2.0% | $383.0M-4.5% | $355.0M-9.0% | $342.0M-14.3% | $358.0M-13.7% | $401.0M-2.0% |
| Operating Income | $37.0Mn/m | $82.0Mn/m | -$35.0M-155.6% | -$139.0Mn/m | -$218.0Mn/m | -$128.0M-356.0% | $63.0M+50.0% | -$509.0M-797.3% |
| EBITDA | $119.0Mn/m | $167.0Mn/m | $44.0M-69.0% | -$46.0Mn/m | -$126.0Mn/m | -$40.0M-129.4% | $142.0M+10.9% | -$421.0M-366.5% |
| Interest Expense | $25.0M+8.7% | $22.0M-8.3% | $24.0M+26.3% | $22.0M+37.5% | $23.0M+27.8% | $24.0M+41.2% | $19.0M+5.6% | $16.0M-20.0% |
| Income Tax | $29.0M-85.4% | $36.0Mn/m | -$32.0M-228.0% | -$2.0Mn/m | $198.0M+1064.7% | -$109.0M-386.8% | $25.0M+78.6% | -$95.0Mn/m |
| Net Income | -$2.0Mn/m | $37.0Mn/m | -$10.0M-150.0% | -$146.0Mn/m | -$427.0Mn/m | -$45.0Mn/m | $20.0M+11.1% | -$430.0M-741.8% |
| EPS (Basic) | -$0.01n/m | $0.18n/m | -$0.05-150.0% | -$0.73n/m | -$2.14n/m | -$0.22n/m | $0.10+11.1% | -$2.13-765.6% |
| EPS (Diluted) | -$0.01n/m | $0.18n/m | -$0.05-150.0% | -$0.73n/m | -$2.14n/m | -$0.22n/m | $0.10+11.1% | -$2.13-765.6% |
| Diluted Shares (Avg) | 199M-0.2% | 201M+0.6% | 200M+0.1% | N/A | 200M-0.7% | 199M-3.1% | 200M-4.2% | N/A |
XRAY Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $5.2B-8.2% | $5.2B-14.3% | $5.2B-13.6% | $5.4B-5.6% | $5.7B-14.7% | $6.1B-12.0% | $6.0B-15.1% | $5.8B-21.9% |
| Current Assets | $2.0B-4.5% | $1.9B-1.9% | $1.8B-6.7% | $2.0B+15.9% | $2.1B+7.9% | $2.0B+11.8% | $2.0B+4.0% | $1.7B-11.5% |
| Cash & Equivalents | $195.0M-46.3% | $239.0M-33.4% | $190.0M-52.3% | $326.0M+19.9% | $363.0M+22.6% | $359.0M+28.7% | $398.0M+36.8% | $272.0M-18.6% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Inventory | $707.0M+3.1% | $665.0M-1.5% | $659.0M+7.7% | $642.0M+13.8% | $686.0M+10.8% | $675.0M+11.0% | $612.0M-0.2% | $564.0M-9.6% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Goodwill | $1.1B-10.6% | $1.1B-25.5% | $1.1B-30.0% | $1.1B-28.1% | $1.3B-34.4% | $1.5B-36.0% | $1.6B-32.0% | $1.6B-34.5% |
| Total Liabilities | $3.8B-8.1% | $3.9B-6.2% | $3.9B-3.2% | $4.1B+7.3% | $4.2B+0.9% | $4.1B+7.2% | $4.0B+4.5% | $3.8B-6.5% |
| Current Liabilities | $1.2B-13.4% | $1.2B+1.6% | $1.2B-32.7% | $1.3B-15.5% | $1.4B-8.9% | $1.2B-11.9% | $1.8B+34.8% | $1.6B+11.5% |
| Non-Current Liabilities | $2.6B-5.5% | $2.7B-9.3% | $2.7B+20.3% | $2.7B+23.6% | $2.8B+6.8% | $2.9B+17.2% | $2.2B-11.4% | $2.2B-16.2% |
| Long-Term Debt | $2.0B-1.6% | $2.0B-10.0% | $2.0B+25.9% | $2.0B+27.0% | $2.0B+12.4% | $2.2B+27.7% | $1.6B-8.8% | $1.6B-11.7% |
| Total Equity | $1.4B-8.3% | $1.4B-31.1% | $1.3B-34.4% | $1.3B-31.1% | $1.5B-40.7% | $2.0B-36.0% | $2.0B-38.3% | $1.9B-41.0% |
| Retained Earnings | -$1.5Bn/m | -$1.5Bn/m | -$1.6Bn/m | -$1.6Bn/m | -$1.4Bn/m | -$925.0M-708.6% | -$848.0M-546.3% | -$835.0M-507.3% |
Not reported in any period shown, so not listed: Accounts Receivable.
XRAY Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $32.0M-59.5% | $99.0M+106.3% | $40.0M+471.4% | $101.0M+16.1% | $79.0M-44.0% | $48.0M-76.9% | $7.0M-72.0% | $87.0M-45.6% |
| Depreciation & Amortization | $82.0M-10.9% | $85.0M-3.4% | $79.0M0.0% | $93.0M+5.7% | $92.0M+3.4% | $88.0M+2.3% | $79.0M-8.1% | $88.0M+3.5% |
| Stock-Based Compensation | $8.0M+33.3% | $9.0M0.0% | $8.0M-20.0% | N/A | $6.0M-50.0% | $9.0M-25.0% | $10.0M-9.1% | N/A |
| Capital Expenditures | $32.0M-17.9% | $44.0M+37.5% | $52.0M+173.7% | $41.0M-19.6% | $39.0M-9.3% | $32.0M-38.5% | $19.0M-44.1% | $51.0M+27.5% |
| Free Cash Flow | $0-100.0% | $55.0M+243.8% | -$12.0Mn/m | $60.0M+66.7% | $40.0M-59.2% | $16.0M-89.7% | -$12.0Mn/m | $36.0M-70.0% |
| Investing Cash Flow | -$43.0Mn/m | -$39.0Mn/m | -$53.0Mn/m | -$45.0Mn/m | -$36.0Mn/m | -$34.0Mn/m | -$17.0Mn/m | -$57.0Mn/m |
| Financing Cash Flow | -$28.0Mn/m | -$11.0Mn/m | -$119.0M-196.7% | -$99.0Mn/m | -$36.0Mn/m | -$68.0Mn/m | $123.0Mn/m | -$38.0Mn/m |
| Dividends Paid | $0-100.0% | $0-100.0% | $32.0M0.0% | $32.0M+3.2% | $32.0M-3.0% | $32.0M-3.0% | $32.0M+10.3% | $31.0M+3.3% |
| Share Buybacks | $13.0Mn/m | N/A | N/A | $0n/m | $0-100.0% | N/A | N/A | $0-100.0% |
XRAY Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.0%+4.2pp | 54.9%+2.6pp | 48.5%-4.5pp | 46.1%-3.2pp | 48.8%-3.3pp | 52.3%+0.4pp | 53.0%-0.1pp | 49.3%-2.3pp |
| Operating Margin | 4.4%+28.5pp | 9.1%+22.8pp | -4.0%-11.2pp | -14.5%+41.8pp | -24.1%+24.5pp | -13.7%-18.8pp | 7.2%+2.8pp | -56.2%-63.5pp |
| Net Margin | -0.2%+47.0pp | 4.1%+8.9pp | -1.1%-3.4pp | -15.2%+32.3pp | -47.2%+4.7pp | -4.8%-4.4pp | 2.3%+0.4pp | -47.5%-54.1pp |
| Return on Equity | -0.1%+28.7pp | 2.7%+5.0pp | -0.8%-1.8pp | -10.9%+11.2pp | -28.9%-9.1pp | -2.3%-2.2pp | 1.0%+0.5pp | -22.1%-24.2pp |
| Return on Assets | 0.0%+7.5pp | 0.7%+1.5pp | -0.2%-0.5pp | -2.7%+4.8pp | -7.5%-0.1pp | -0.7%-0.7pp | 0.3%+0.1pp | -7.5%-8.4pp |
| Current Ratio | 1.63+0.2x | 1.63-0.1x | 1.53+0.4x | 1.51+0.4x | 1.47+0.2x | 1.69+0.4x | 1.10-0.3x | 1.10-0.3x |
| Debt-to-Equity | 1.46+0.1x | 1.48+0.3x | 1.52+0.7x | 1.50+0.7x | 1.36+0.6x | 1.13+0.6x | 0.79+0.3x | 0.82+0.3x |
| Liabilities-to-Equity | 2.830.0x | 2.85+0.8x | 2.97+1.0x | 3.05+1.1x | 2.82+1.2x | 2.10+0.8x | 2.01+0.8x | 1.96+0.7x |
| Asset Turnover | 0.160.0x | 0.170.0x | 0.170.0x | 0.180.0x | 0.160.0x | 0.150.0x | 0.150.0x | 0.160.0x |
| FCF Margin | 0.0%-4.4pp | 6.1%+4.4pp | -1.4%0.0pp | 6.2%+2.3pp | 4.4%-5.9pp | 1.7%-14.1pp | -1.4%-0.4pp | 4.0%-7.9pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| DENTSPLY SIRONA Inc. XRAY | FY2025 | $3.7B | -$598.0M | -16.3% | $1.7B | 28/100 |
| Azenta, Inc. AZTA | FY2026 | $621.7M | -$167.0M | -26.9% | $1.9B | 47/100 |
| LeMaitre Vascular, Inc. LMAT | FY2025 | $249.6M | $57.7M | 23.1% | $1.7B | 78/100 |
| Kestra Medical Technologies, Ltd. KMTS | FY2026 | $95.1M | -$131.6M | N/A | $1.5B | 51/100 |
| Staar Surgical Co STAA | FY2025 | $239.4M | -$80.4M | -33.6% | $1.2B | 34/100 |
| Embecta Corp. EMBC | FY2025 | $1.1B | $95.4M | 8.8% | $341.1M | 58/100 |
Where DENTSPLY SIRONA Inc. Ranks
Frequently Asked Questions
DENTSPLY SIRONA Inc. (XRAY) reported $3.7B in total revenue for fiscal year 2025. This represents a -3.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
DENTSPLY SIRONA Inc. (XRAY) revenue declined by 3.0% year-over-year, from $3.8B to $3.7B in fiscal year 2025.
No, DENTSPLY SIRONA Inc. (XRAY) reported a net loss of $121.0M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $598.0M, with a net profit margin of -16.3%.
DENTSPLY SIRONA Inc. (XRAY) had EBITDA of -$70.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
As of fiscal year 2025, DENTSPLY SIRONA Inc. (XRAY) had $326.0M in cash and equivalents against $2.0B in long-term debt.
DENTSPLY SIRONA Inc. (XRAY) had a gross margin of 50.0% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
DENTSPLY SIRONA Inc. (XRAY) had an operating margin of -11.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
DENTSPLY SIRONA Inc. (XRAY) had a net profit margin of -16.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Yes, DENTSPLY SIRONA Inc. (XRAY) paid $0.64 per share in dividends during fiscal year 2025.
DENTSPLY SIRONA Inc. (XRAY) has a return on equity of -44.7% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
DENTSPLY SIRONA Inc. (XRAY) generated $104.0M in free cash flow during fiscal year 2025. This represents a -63.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
DENTSPLY SIRONA Inc. (XRAY) generated $235.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
DENTSPLY SIRONA Inc. (XRAY) had $5.4B in total assets as of fiscal year 2025, including both current and long-term assets.
DENTSPLY SIRONA Inc. (XRAY) invested $131.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
DENTSPLY SIRONA Inc. (XRAY) invested $150.0M in research and development during fiscal year 2025.
DENTSPLY SIRONA Inc. (XRAY) had a current ratio of 1.51 as of fiscal year 2025, which is generally considered healthy.
DENTSPLY SIRONA Inc. (XRAY) had a debt-to-equity ratio of 1.50 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
DENTSPLY SIRONA Inc. (XRAY) had a liabilities-to-equity ratio of 3.05 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
DENTSPLY SIRONA Inc. (XRAY) had a return on assets of -11.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
DENTSPLY SIRONA Inc. (XRAY) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $1.7B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
DENTSPLY SIRONA Inc. (XRAY) trades at 0.5x sales, its market capitalization divided by $3.6B revenue, trailing 12 months to September 30, 2026. The market capitalization is $1.7B as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
DENTSPLY SIRONA Inc. (XRAY) has an Altman Z-Score of 0.41, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
DENTSPLY SIRONA Inc. (XRAY) has a Piotroski F-Score of 5 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
DENTSPLY SIRONA Inc. (XRAY) reported a net loss of $598.0M while generating $235.0M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
DENTSPLY SIRONA Inc. (XRAY) reported an operating loss of $422.0M against $88.0M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
DENTSPLY SIRONA Inc. (XRAY) scores 28 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.